Search / Trial NCT00001402

PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Dec 9, 2002

Apply for Trial

Trial Information

Current as of June 14, 2024

Completed

Keywords

Dilated Cardiomyopathy Hibernating Myocardium Ischemic Cardiomyopathy Metoprolol Stress Thallium Scintigraphy Congestive Cardiomyopathy Congestive Heart Failure Heart Failure

Description

Deterioration in left ventricular function, which is characteristic in patients with congestive heart failure, appears to be a multifactorial process. Beta-blockers appear to reverse the deterioration and frequently improve left ventricular function in patients with both ischemic and non-ischemic cardiomyopathies. The mechanism by which beta-blockers improve ejection fraction is not known. Although it is well established that regional flow, function and metabolism may improve after coronary revascularization whether beta-blocker therapy will have similar salutary results in patients with co...

Gender

All

Eligibility criteria

  • Left ventricular ejection fraction by radionuclide angiography of less than or equal to 40%.
  • New York Heart Association class II, III or IV symptoms on standard heart failure medications which my include digoxin, diuretics and angiotensin converting enzyme inhibitors for at least one month prior to enrollment.
  • Ischemic cardiomyopathy if enzymes document an MI or 70% or greater stenosis in one major vessel.
  • Dilated cardiomyopathy-if no coronary disease.
  • No pregnant or lactating women.
  • No women of child-bearing age not on proven birth control.
  • No severe hepatic or renal disease.
  • No diabetes mellitus or fasting glucose greater than or equal to 120 mg/dl.
  • No primary valvular heart disease.
  • No PTCA or CABG within 3 months of enrollment.
  • No history of myocardial infarction or unstable angina within past 2 months.
  • No resting heart rate less than 60 bpm.
  • No A-V block greater than 1 degree block without pacemaker.
  • No severe ETOH abuse within 6 months of enrollment.
  • No severe bronchospasm.

Attachments

readout_NCT00001402_2024-06-14.pdf

4.5 MB

NCT00001402_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0